Hennigsdorf/Berlin (Germany), October 13, 2022 – Adrenomed AG, the vascular integrity company, today announced its participation in upcoming industry and investor conferences. The Adrenomed management team will be available for meetings to present and discuss the plans for its global phase 3 study in septic shock:
October 24 – 26, 2022, Leipzig Messe, Germany
November 2 – 4, 2022, virtual
Dr. Richard Jones, CEO of Adrenomed, David Germonpré, CFO and Dr. Martina Kalle-Brune, Head of Business Development and Strategic Alliances, will be available onsite for networking, partnering and one-on-one discussions. Furthermore, our management team will showcase Adrenomed’s goals and development strategy in a company presentation in Leipzig on Tuesday, October 25, at 1:00 pm, in Multi-purpose room 4.
LSX Inv€$tival Showcase™ in partnership with Jefferies (link)
November 14, 2022, Old Billingsgate London, UK
Dr. Richard Jones, CEO and David Germonpré, CFO will be available for 1:1 partnering and a company showcase.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab (INN: enibarcimab) is a first-in-class non-blocking monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.
Martina Kalle-Brune, Ph.D.
phone: +49 (0)3302 207780
MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 2102280